Tarcocimab in DR: the GLOW2 study in DR features a similar study design as the successful GLOW1 study, with the benefit of an additional 3rd initiating dose DRSS: diabetic retinopathy severity score; GLOW 1 study NCT05066230; GLOW2 study NCT06270836 Proportion of patients developing any sight- threatening complication from Baseline to Week 48 Key Secondary Endpoint ~90% risk reduction for developing a pre- specified sight- threatening complication with tarcocimab Primary Endpoint Tarcocimab demonstrated superiority in ≥2- step and ≥3-step improvement in DRSS Proportion of patients with ≥2-Step improvement in DRSS from Baseline to Week 48 GLOW1 study results GLOW2 study design Primary Endpoint Initiating doses 25